Foslevodopa/Foscarbidopa Reduces Troublesome Dyskinesia in People with Advanced Parkinson’s Disease in Two Phase Three Clinical Trials (P3-17.011)

Key Points

• The study aims to assess the effectiveness of foslevodopa/foscarbidopa in reducing troublesome dyskinesia in advanced Parkinson’s disease.
• Conducted two phase 3 clinical trials focusing on patients with advanced Parkinson's disease.
• Treatment with foslevodopa/foscarbidopa was the primary intervention evaluated.
• Significant reduction in troublesome dyskinesia was observed in patients treated with foslevodopa/foscarbidopa compared to baseline.
• Results demonstrated effective management of dyskinesia symptoms in advanced Parkinson's disease patients.